February 2025 in “Journal of Receptors and Signal Transduction” EGCG may help regrow hair by inhibiting a specific enzyme.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
July 2024 in “Reactions Weekly” July 2024 in “Journal of Investigative Dermatology” Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
4 citations
,
July 2019 in “Experimental Dermatology” 2-deoxy D-glucose does not help with hair regrowth in alopecia areata.
April 2020 in “Rheumatology” Many patients with Giant Cell Arteritis did not follow their steroid treatment plans properly.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
5-ARI therapy may help prevent prostate cancer progression.
August 2023 in “European journal of dermatology/EJD. European journal of dermatology” Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.
November 2022 in “CARDIOMETRY” A group has developed therapies that show promise for treating cancer and various other conditions.
October 2012 in “Institutional Repositories DataBase (IRDB)” Stem cell treatment can effectively regrow hair.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
11 citations
,
June 2023 in “Drug Delivery and Translational Research” The gel with apocynin-loaded nanoparticles shows promise for treating rheumatoid arthritis.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
February 2026 in “Journal of Sylva Indonesiana” Avicennia marina heartwood extract shows strong antioxidant potential for health benefits.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
April 2024 in “Skin health and disease” Using a special skin cream with gabapentin helped reduce symptoms of a certain scalp condition but didn't change nerve fibers or skin chemicals.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.